utility-head-001

Prescribing Information    |    Important Safety Information For US Healthcare Professionals Only For the treatment of partial‑onset seizures in adults Prescribing Information    |    Important Safety Information For US Healthcare Professionals Only For the treatment of partial-onset seizures in adults

utility-head-002

Prescribing Information    |    Important Safety Information For US Healthcare Professionals Only For the treatment of partial‑onset seizures in adults Prescribing Information    |    Important Safety Information For US Healthcare Professionals Only For the treatment of partial-onset seizures in adults

utility-greet-001

hero-gen-001

Switch on XCOPRI sooner A chance at zero seizures can’t wait. Switch on XCOPRI sooner A chance at zero seizures can’t wait.

hero-gen-002

Help light the way forward with the power of once-daily XCOPRI1 A chance at zero seizures can’t wait. Help light the way forward with the power of once-daily XCOPRI1 A chance at zero seizures can’t wait.

ref-hero-gen-002

hero-urg-001

Uncontrolled seizures continue to be a reality for many patients1 The consequences of seizures—physical, emotional, and cognitive—can take their toll on patients’ daily lives.

ref-hero-urg-001

hero-moa-001

ref-hero-moa-001

hero-eff-001

hero-saf-001

ref-hero-saf-001

hero-tol-001

hero-acc-001

hero-dos-001

Convenient once-daily dosing1 XCOPRI offers a personalized treatment approach for your patients.

ref-hero-dos-001

body-urg-001

Patients have a lot to lose with just 1 seizure When seizures remain uncontrolled, patients are1*: ~6x more likely to have depression 4.5x more likely to be prevented from driving 3x more likely to experience limitations in employment 2x more likely to have limits in education Patients have a lot to lose with just 1 seizure When seizures remain uncontrolled, patients are1*: ~6x more likely to have depression 4.5x more likely to be prevented from driving 3x more likely to experience limitations in employment 2x more likely to have limits in education Patients with seizures have an increased risk of SUDEP2† Up to 9.3 deaths per 1000 person-years in patients with refractory epilepsy3 Secondary generalized tonic-clonic seizures put patients at a 30x higher risk for SUDEP compared to other seizure types4 Up to 9.3 deaths per 1000 person-years in patients with refractory epilepsy3 Secondary generalized tonic-clonic seizures put patients at a 30x higher risk for SUDEP compared to other seizure types4 * Based on data that compared patients who had ≥1 seizure in the past 5 years with those who experienced no seizures in the past 5 years. † Based on data that compared patients who had ≥1 seizure in the previous year with those who had zero seizures in the previous year. SUDEP=sudden unexpected death in epilepsy.

ref-body-urg-001

body-urg-002

Many patients have a history of being let down During the past 3 decades, despite new ASMs coming to market, seizure freedom rates have remained nearly the same.1,2* Rates of zero seizures by decade of approval for a range of ASMs3† 1990-1999 2.1%-8.7% vs 0%-2.2% with placebo4,5 2000-2009 2.2%-7.4% vs 0.8%-1.2% with placebo6,7 2010-2019 2.0%-8.2% vs 0%-2% with placebo8-10 1990-1999 2.1%-8.7% vs 0%-2.2% with placebo4,5 2000-2009 2.2%-7.4% vs 0.8%-1.2% with placebo6,7 2010-2019 2.0%-8.2% vs 0%-2% with placebo8-10 Prior to the 1990s, there was little information on seizure freedom rates with ASMs used as add-on therapy—and even less information about how these rates were determined.3 * Seizure freedom was defined as a patient experiencing no seizures for the previous 12 months or longer.1 † Data from pivotal trials. ASMs=anti-seizure medications.

ref-body-urg-002

body-urg-003

Patients with seizures have an increased risk of SUDEP1* Up to 9.3 deaths per 1000 person-years in patients with refractory epilepsy2 Secondary generalized tonic-clonic seizures put patients at a 30x higher risk for SUDEP compared to other seizure types3 Up to 9.3 deaths per 1000 person-years in patients with refractory epilepsy2 Secondary generalized tonic-clonic seizures put patients at a 30x higher risk for SUDEP compared to other seizure types3 * Based on data that compared patients who had ≥1 seizure in the previous year with those who had zero seizures in the previous year. SUDEP=sudden unexpected death in epilepsy.

ref-body-urg-003

body-urg-004

Patients with uncontrolled seizures have an increased risk of comorbidities1*† Cardiac and Metabolic 1.5-2x more likely to have atrial fibrillation (AFib) Neuro-psychiatric 3x more likely to have non-epileptic seizures Neurologic 1.5-2x more likely to have brain trauma 1.5-2x more likely to develop dementia/Alzheimer’s 1.5-2x more likely to have a stroke Cardiac and Metabolic 1.5-2x more likely to have atrial fibrillation (AFib) Neuro-psychiatric 3x more likely to have non-epileptic seizures Neurologic 1.5-2x more likely to have brain trauma 1.5-2x more likely to develop dementia/Alzheimer’s 1.5-2x more likely to have a stroke * Incidence of comorbidities in patients with uncontrolled vs controlled epilepsy following initiation of first-line and third-line ASM. † Uncontrolled epilepsy was defined by ≥1 of the following events: seizure-related inpatient visit, seizure-related emergency room visit, or new ASM line of therapy initiation. ASM=anti-seizure medication.

ref-body-urg-004

body-eff-001

Powerful reduction across multiple seizure types Results from a study of patients with a median of 9 seizures/28 days at baseline1,2 Additional secondary outcome: Median percentage reduction in 28-day seizure frequency in partial-onset seizure subtypes (12-week maintenance phase)1,3 See full study design and population   See full study design and population   * Partial-onset=focal; simple partial=focal aware; complex partial=focal unaware; secondary generalized tonic-clonic=focal to bilateral tonic-clonic.4 † Only patients with simple partial motor seizures were included in the study.

ref-body-eff-001

body-eff-002

Zero seizure rates achieved within 4 weeks and increased over time1 Results from a post hoc analysis of a phase 3 study: Percentage of patients with 1-2 seizures/28 days at baseline who achieved zero seizures within the first 4 weeks taking XCOPRI See full study design   Limitations: This post hoc analysis of an open-label phase 3 study of XCOPRI did not include a control arm. These data are descriptive and representative of an enriched population with a relatively small number of patients. Appropriate multiplicity adjustments were not applied.

ref-body-eff-002

body-eff-003

Long-term zero seizure rates seen for 12 months or longer1 Results from a post hoc analysis of a phase 3 study: Zero seizures achieved with XCOPRI regardless of baseline seizure frequency See full study design   * Among patients continuing cenobamate at data cut-off. Limitations: This post hoc analysis of an open-label phase 3 study of XCOPRI did not include a control arm. These data are descriptive and representative of an enriched population with a relatively small number of patients. Appropriate multiplicity adjustments were not applied.

ref-body-eff-003

body-eff-004

Reducing concomitant ASM drug load with XCOPRI Results from a post hoc analysis of a phase 3 study: 62% of patients on XCOPRI discontinued and/or reduced 1 or more ASMs across all drug classes (110/177)1 Reducing concomitant ASM drug load with XCOPRI Results from a post hoc analysis of a phase 3 study: 62% of patients on XCOPRI discontinued and/or reduced 1 or more ASMs across all drug classes (110/177)1 In this group of patients, there was no increase or addition of concomitant ASMs.1* The most common concomitant ASMs used at baseline included lacosamide, levetiracetam, lamotrigine, zonisamide, and clobazam.2 * Sodium channel blockers, synaptic vesicle protein 2A ligands, benzodiazepines, and others. ASMs=anti-seizure medications. Limitations: This post hoc analysis of an open-label phase 3 study of XCOPRI did not include a control arm. These data are descriptive and representative of an enriched population with a relatively small number of patients. Appropriate multiplicity adjustments were not applied. In this group of patients, there was no increase or addition of concomitant ASMs.1* The most common concomitant ASMs used at baseline included lacosamide, levetiracetam, lamotrigine, zonisamide, and clobazam.2 * Sodium channel blockers, synaptic vesicle protein 2A ligands, benzodiazepines, and others. ASMs=anti-seizure medications. Limitations: This post hoc analysis of an open-label phase 3 study of XCOPRI did not include a control arm. These data are descriptive and representative of an enriched population with a relatively small number of patients. Appropriate multiplicity adjustments were not applied.

ref-body-eff-004

body-eff-005

Switch on XCOPRI sooner #1 branded ASM prescribed by epileptologists* Over 275,000 patients prescribed worldwide and counting† Copay comparable to generics‡ 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ 10+ years of clinical trial and real-world experience Well-studied safety with 5-year retention data1,2 #1 branded ASM prescribed by epileptologists* Over 275,000 patients prescribed worldwide and counting† Copay comparable to generics‡ 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ 10+ years of clinical trial and real-world experience Well-studied safety with 5-year retention data1,2 * By NBRx, as of July 2025. † Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA. ‡ IQVIA, Patient Cost Disclosure 12 months ending April 2025. § Managed Markets Insight & Technology, LLC, database as of July 2025.

ref-body-eff-005

body-moa-001

XCOPRI reduces neuronal excitability through a unique dual MOA1-5* Positive allosteric modulator of the GABAA receptor3,4 Further enhances inhibition by GABAergic neurons Inhibits persistent sodium current3,5 Preferentially blocks the sodium channel–mediated persistent current Positive allosteric modulator of the GABAA receptor3,4 Further enhances inhibition by GABAergic neurons Inhibits persistent sodium current3,5 Preferentially blocks the sodium channel–mediated persistent current Different from other sodium inhibitors, XCOPRI preferentially inhibits persistent sodium current, rather than transient current. XCOPRI also enhances GABAA-mediated inhibition. These are both important targets in epilepsy to maintain balance between excitation and inhibition.1-5 Different from other sodium inhibitors, XCOPRI preferentially inhibits persistent sodium current, rather than transient current. XCOPRI also enhances GABAA-mediated inhibition. These are both important targets in epilepsy to maintain balance between excitation and inhibition.1-5 * The precise mechanism by which XCOPRI exerts its anticonvulsant activity is unknown.3

ref-body-moa-001

body-saf-001

10+ years of clinical trial and real-world experience Over 275,000 patients prescribed worldwide* * Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA.

body-tol-001

body-tol-002

Cognition with XCOPRI Based on a post hoc analysis of pooled populations across phase 2 and phase 3 studies Rates of cognitive TEAEs observed with XCOPRI were 2.3% vs 0.9% with placebo.1* Based on a post hoc analysis of pooled populations across phase 2 and phase 3 studies Rates of cognitive TEAEs observed with XCOPRI were 2.3% vs 0.9% with placebo.1* Limitations: Cognitive symptoms were evaluated using non-standardized measures including spontaneous patient self-reporting, which may have led to underreporting of mild or intermittent symptoms. Baseline cognitive comorbidities were assessed retrospectively and could not be directly compared with TEAEs. Potential confounding effects from concomitant anti-seizure medications further limit interpretation of cognitive findings. * Patients with focal epilepsy were assessed on memory impairment, word-finding difficulty, mathematical difficulty, and disturbances in attention. TEAEs=treatment-emergent adverse events.

ref-body-tol-002

body-tol-003

Weight with XCOPRI Low rates of weight change reported with XCOPRI in pivotal trials1 XCOPRI (3/442) vs placebo (0/216) Low rates of weight change reported with XCOPRI in pivotal trials1 XCOPRI (3/442) vs placebo (0/216)

ref-body-tol-003

body-tol-004

Long-term retention rates1 Pooled data from the clinical development program: At 5 years, the majority of patients remained on treatment About the analysis: These retention data are based on Kaplan-Meier estimates of time to discontinuation of open-label XCOPRI in the pooled population from 3 clinical studies. Conclusions of long-term efficacy and safety should not be drawn based on these data. 80% of patients were on 2-3 concomitant anti-seizure medications at the start of open-label XCOPRI treatment. In this pooled population, the median duration of XCOPRI exposure was 2.8 years, with a median XCOPRI modal dose of 200 mg/day.

ref-body-tol-004

body-dos-001

Overview of dosing with XCOPRI1 Convenient once-daily dosing and a half-life of 50-60 hours Take any time, whole or crushed, with or without food Can be taken as monotherapy or adjunctive therapy Convenient once-daily dosing and a half-life of 50-60 hours Take any time, whole or crushed, with or without food Can be taken as monotherapy or adjunctive therapy Liver function tests should be conducted prior to starting XCOPRI to establish baseline liver function if results are not available from the past 3 months. 200 mg is the maximum dosage for patients with mild or moderate hepatic impairment. XCOPRI is not recommended for use in patients with severe hepatic impairment.

ref-body-dos-001

body-dos-002

Additional blister packs and bottles available. Additional blister packs and bottles available. Flexibility to meet your patients’ unique needs1 • Blister packs can simplify the titration schedule when starting XCOPRI • Bottles and maintenance blister packs allow for adjustments to find the right dosage for each patient

ref-body-dos-002

body-tit-001

Personalize your approach with once-daily XCOPRI1 XCOPRI is titrated at 2-week intervals. • Convenient once-daily dosing and a half-life of 50-60 hours • Taken any time, whole or crushed, with or without food • Can be taken as monotherapy or adjunctive therapy Liver function tests should be conducted prior to starting XCOPRI to establish baseline liver function if results are not available from the past 3 months. 200 mg is the maximum dosage for patients with mild or moderate hepatic impairment. XCOPRI is not recommended for use in patients with severe hepatic impairment. * Additional blister packs and bottles available. Flexibility to meet your patients’ unique needs1 • Blister packs can simplify the titration schedule when starting XCOPRI • Bottles and maintenance blister packs allow for adjustments to find the right dosage for each patient

ref-body-tit-001

body-acc-001

Switch on XCOPRI sooner 3 out of 4 patients have access as initial therapy, meaning they do not need to try and fail other ASMs (including generics) for XCOPRI to be covered by their insurance* Widely accessible 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI* If a prior authorization (PA) is required, ~90% of PAs are approved based solely on indication* Start at $0 Patients can receive their first month’s prescription for $0 through the Trial Offer or starter sample program† Low copay Approximately 95% of patients with Commercial, Medicare, or Medicaid insurance have a $0-$20 copay for XCOPRI (comparable to the cost of generic ASMs)‡ Widely accessible 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI* If a prior authorization (PA) is required, ~90% of PAs are approved based solely on indication* Start at $0 Patients can receive their first month’s prescription for $0 through the Trial Offer or starter sample program† Low copay Approximately 95% of patients with Commercial, Medicare, or Medicaid insurance have a $0-$20 copay for XCOPRI (comparable to the cost of generic ASMs)‡ * Managed Markets Insight & Technology, LLC, database as of July 2025. † Eligibility requirements and terms and conditions will apply. ‡ IQVIA, Patient Cost Disclosure 12 months ending April 2025. ASMs=anti-seizure medications.

body-acc-002

XCOPRI is widely accessible 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI.* * Managed Markets Insight & Technology, LLC, database as of July 2025. XCOPRI is widely accessible 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI.* * Managed Markets Insight & Technology, LLC, database as of July 2025.

body-acc-003

Copay comparable to generic ASMs Approximately 95% of patients with Commercial, Medicare, or Medicaid insurance have a $0-$20 copay for XCOPRI.* * IQVIA, Patient Cost Disclosure 12 months ending April 2025. ASMs=anti-seizure medications. Copay comparable to generic ASMs Approximately 95% of patients with Commercial, Medicare, or Medicaid insurance have a $0-$20 copay for XCOPRI.* * IQVIA, Patient Cost Disclosure 12 months ending April 2025. ASMs=anti-seizure medications.

body-acc-004

Covered as first ASM for most patients 3 out of 4 patients have access as initial therapy, meaning they do not need to try and fail other ASMs (including generics) for XCOPRI to be covered by their insurance.* * Managed Markets Insight & Technology, LLC, database as of July 2025. ASM=anti-seizure medication. Covered as first ASM for most patients 3 out of 4 patients have access as initial therapy, meaning they do not need to try and fail other ASMs (including generics) for XCOPRI to be covered by their insurance.* * Managed Markets Insight & Technology, LLC, database as of July 2025. ASM=anti-seizure medication.

body-acc-005

XCOPRI is available for convenient home delivery through Amazon Pharmacy E-scribe XCOPRI right to Amazon Pharmacy, just like any other pharmacy.

body-acc-006

XCOPRI is available to order at all pharmacies Need additional support? We’re here to help your patients get started on XCOPRI and stay on with a variety of support services.

body-acc-007

Get support with SK Life Science Navigator For patients • Free product to eligible patients who are uninsured, underinsured, or experiencing financial hardship • Help to locate XCOPRI if your patient’s local pharmacy does not have it in stock For your practice • Help to identify whether a patient’s insurance plan covers XCOPRI • If a PA is required, SKLSI Navigator will provide the information that is needed • Downloadable sample letter of appeal, medical necessity, and more PA=prior authorization; SKLSI=SK Life Science, Inc.

body-acc-008

Specialty pharmacies can help get quick access to XCOPRI and PA support Convenient home delivery, including urgent or emergency requests Refill reminders Resolving PA requests Convenient home delivery, including urgent or emergency requests Refill reminders Resolving PA requests PA=prior authorization.

body-gen-001

XCOPRI resources and downloadable tools for your patients and practice Expert insights Hear from your peers who have switched on the power of XCOPRI—and are seeing meaningful results. Expert insights Hear from your peers who have switched on the power of XCOPRI—and are seeing meaningful results. XCOPRI patients Real patients. Real progress. See how XCOPRI is helping light the way forward to fewer seizures. XCOPRI patients Real patients. Real progress. See how XCOPRI is helping light the way forward to fewer seizures. Downloadable PDFs Our clinical resources and patient support tools are designed to help you make informed decisions, every step of the way. Downloadable PDFs Our clinical resources and patient support tools are designed to help you make informed decisions, every step of the way. FAQs Explore answers to common questions about XCOPRI. FAQs Explore answers to common questions about XCOPRI.

cta-urg-001

See why a chance at zero seizures can’t wait.

cta-eff-001

Discover the power of once-daily XCOPRI.1

ref-cta-eff-001

cta-moa-001

See how the XCOPRI MOA differs from other sodium inhibitors.1-5 MOA=mechanism of action.

ref-cta-moa-001

cta-saf-001

See the 10+ years of clinical trial and real-world experience with XCOPRI.

cta-tol-001

Well-studied safety: See XCOPRI clinical trial data.1

ref-cta-tol-001

cta-dos-001

XCOPRI offers once-daily dosing with a personalized treatment approach.1

ref-cta-dos-001

cta-tit-001

Learn about convenient blister packs to help patients start and stay on XCOPRI.1

Learn about convenient blister packs to help patients start and stay on XCOPRI.1

ref-cta-tit-001

cta-acc-001

Starting a patient on XCOPRI? Get the access information you need.

cta-gen-001

Explore tools for your patients and practice.

Explore tools for your patients and practice.

cta-gen-002

Getting Patients Started on XCOPRI Guide Get guidance on coverage, prescribing XCOPRI, and support programs for your practice and patients. Getting Patients Started on XCOPRI Guide Get guidance on coverage, prescribing XCOPRI, and support programs for your practice and patients.

cta-gen-003

Switching On XCOPRI Flashcard Find important information about prescribing XCOPRI, how to titrate, and drug load reduction. Switching On XCOPRI Flashcard Find important information about prescribing XCOPRI, how to titrate, and drug load reduction.

cta-gen-004

For patients: XCOPRI Brochure This brochure includes information for patients on how to take XCOPRI, potential side effects, and a patient-friendly version of XCOPRI study data. For patients: XCOPRI Brochure This brochure includes information for patients on how to take XCOPRI, potential side effects, and a patient-friendly version of XCOPRI study data.

cta-gen-005

For patients: S.T.E.P.S. Discussion Guide Based on a survey of patients, caregivers, and healthcare providers, this guide is designed to help foster the patient/care team relationship and help patients reach their goals. Available in English and Spanish. For patients: S.T.E.P.S. Discussion Guide Based on a survey of patients, caregivers, and healthcare providers, this guide is designed to help foster the patient/care team relationship and help patients reach their goals. Available in English and Spanish.

cta-gen-006

For patients: Next Steps Brochure This brochure helps patients understand what to expect when starting XCOPRI, including guidance on filling their prescription, copay information, support programs, potential side effects, and patient testimonials. For patients: Next Steps Brochure This brochure helps patients understand what to expect when starting XCOPRI, including guidance on filling their prescription, copay information, support programs, potential side effects, and patient testimonials.

cta-moa-002

See how XCOPRI works Key opinion leader Dr. Raman Sankar explains how XCOPRI reduces neuronal excitability through a dual mechanism of action.1-5* * The precise mechanism by which XCOPRI exerts its anticonvulsant activity is unknown.3 See how XCOPRI works Key opinion leader Dr. Raman Sankar explains how XCOPRI reduces neuronal excitability through a dual mechanism of action.1-5* * The precise mechanism by which XCOPRI exerts its anticonvulsant activity is unknown.3

ref-cta-moa-002

utility-end-001

ref-utility-end-001

utility-end-002

ref-utility-end-002

utility-end-003

ref-utility-end-003

utility-isipre-001

utility-isipre-002

utility-isi-001

utility-foot-001

If you no longer wish to receive email communications from XCOPRI, please unsubscribe or manage your communication preferences. SK Life Science, Inc. 461 From Road Paramus, NJ 07652 Tel: 1-201-421-3800 © 2026 SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd. PM-US-XCOP-1398 4/26 SK Life Science, Inc. 461 From Road Paramus, NJ 07652 Tel: 1-201-421-3800 © 2026 SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd. PM-US-XCOP-1398 4/26